01Decision question
02Executive answer
Begin with a narrow, high-burden workflow where human authority remains clear, evidence can be audited, and improvement can be measured. Avoid broad “AI transformation” programs without workflow ownership, governance, and implementation capacity.
03Scope
Operational and administrative workflows within a single organization. Excludes autonomous clinical decision-making, diagnostic device regulation, and enterprise data-platform replacement.
04Key findings
- Buyers increasingly weight governance, auditability, and data control alongside model performance.
- The strongest early value sits in high-burden, well-bounded workflows rather than broad transformation.
- Implementation capacity — not model access — is the most common failure point.
- Measurable baselines are frequently missing, which makes value hard to prove after deployment.
05Evidence base
| Signal | What it indicates | Confidence |
|---|---|---|
| Procurement language emphasising explainability and audit | Governance is becoming a purchase requirement | High |
| Staffing pressure in documentation-heavy workflows | Clear burden to target first | High |
| Uneven integration and change-management readiness | Execution risk dominates model risk | Developing |
| Inconsistent baseline outcome measurement | Value will be contested without baselines | Developing |
Source notes: synthesis of publicly observable buyer behaviour. In the full brief each row links to a dated primary source and names the analyst who reviewed it.
06Market & regulatory context
Adoption is shaped less by capability and more by trust: data governance, clinical safety, and accountability requirements determine what can be deployed and how quickly. Buyers reward vendors who can prove workflow fit and evidence provenance.
07Scenario comparison
| Scenario | Recommended posture |
|---|---|
| Governance requirements tighten further | Advantage to organizations that start narrow with auditable workflows |
| Requirements stay stable | Prioritise measurable burden reduction and speed to value |
| Broad mandate imposed top-down | Resist scope without workflow owners and implementation capacity |
08Counterarguments
- “Start broad to build momentum.” Broad programs without owners tend to stall and erode trust.
- “Model quality is what matters.” Governance and integration usually decide adoption before model quality does.
09Risks
- No measurable baseline, so value cannot be demonstrated.
- Unclear human authority in the workflow.
- Change-management capacity is underestimated.
10Assumptions
- A single workflow owner can be appointed.
- Governance review can be completed within the budget cycle.
- Baseline data can be captured before deployment.
11Recommendation
Select one high-burden, well-bounded workflow. Appoint a clinical and operational owner, define success and stop conditions, complete governance review, capture a baseline, and run a time-bounded validation before any scaling decision.
12What would change this recommendation
- A governance regime that blocks the chosen workflow.
- Evidence that the burden is smaller than assumed.
- Absence of a credible workflow owner.
13Next 30 / 60 / 90 days
- 30Choose the workflow, appoint the owner, define success and stop conditions.
- 60Complete governance review and capture the baseline.
- 90Run the validation and make an evidence-based scale-or-stop decision.
14Confidence assessment
High. The direction is supported by consistent, observable buyer behaviour. Confidence would fall if governance requirements shifted sharply or if baseline data proved unavailable.
15Authorship
Published briefs carry named authorship and a named reviewer; role titles are shown on public excerpts.